Background Addition of trastuzumab to first-line chemotherapy improves overall survival in
patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of …

Immune Checkpoint Inhibitors and Tumor Mutational Burden The FDA has approved immune
checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations …

Purpose: Gastroesophageal adenocarcinoma (GEA) has a poor prognosis and few therapeutic
options. Utilizing a 73-gene plasma-based next-generation sequencing (NGS) cell-free …

Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low
immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease control in …

Previous anti-EGFR trials in unselected patients with gastroesophageal adenocarcinoma (GEA)
were resoundingly negative. We identified EGFR amplification in 5% (19/363) of …

POLE proofreading deficiency leads to high tumor mutational burden with high tumor-infiltrating
lymphocytes and predicts anti–PD-1 efficacy in mismatch repair–proficient tumors. …

PURPOSE Circulating tumor DNA (ctDNA) analyses allow for postoperative risk
stratification in patients with curatively treated colon and breast cancers. Use of ctDNA in …

Pembrolizumab is a monoclonal antibody directed against PD-1 that is US FDA approved
for treatment of advanced PD-L1 positive gastric and gastroesophageal junction …

Objective: The microbiome is hypothesized to have a significant impact on cancer development.
In gastric cancer (GC), Helicobacter pylori is an established class I carcinogen. However…

Objective: To evaluate the efficacy of chemotherapy in patients with microsatellite instability (MSI)-high
gastric cancer. Background: Although MSI-high gastric cancer is associated with …